Here are the Form 4 insider transactions from Apimeds Pharmaceuticals US, Inc. (APUS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow APUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APUS filings page.
Apimeds Pharmaceuticals US, Inc. (APUS) filed an amended Form 4 to correct how an insider’s holdings are reported. The filing shows that 4,316,618 shares of common stock are held indirectly through Apimeds Inc. (“Apimeds Korea”), a wholly owned subsidiary of the reporting person.
The amendment explains that earlier filings incorrectly showed a Convertible Promissory Note of $184,833 and the related common shares as indirectly owned through Apimeds Korea. As of May 12, 2025, the reporting person had direct beneficial ownership of 2,099,747 common shares and indirect beneficial ownership of 4,316,618 common shares held by Apimeds Korea. The insider also disclaims beneficial ownership of the subsidiary-held shares for certain legal purposes.
Apimeds Pharmaceuticals US, Inc. (APUS) — Form 4 insider activity: A director reported the grant of a stock option for 10,000 shares with an exercise price of $2.67 per share on 11/11/2025. The option expires on 11/11/2035 and was reported as directly owned.
The award vests in quarterly installments beginning October 1, 2025, becoming fully vested after three years. The option is not exercisable until stockholder approval is obtained to amend the company’s incentive plan to increase available shares. The award will vest in full upon a Change in Control as defined in the plan.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a director’s stock option grant. On 11/11/2025, the reporting person received an option to buy 10,000 shares of common stock at an exercise price of $2.67 per share, expiring on 11/11/2035. The award was coded as an acquisition and priced at $0 for the derivative grant, with 10,000 derivative securities beneficially owned directly after the transaction.
The option vests in quarterly installments beginning October 1, 2025 over three years and becomes exercisable only after stockholder approval of an amendment to increase shares available under the incentive plan. It vests in full upon a Change in Control as defined in the plan.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a Form 4 for a director showing a grant of a stock option for 10,000 shares at an exercise price of $2.67 on 11/11/2025.
The option expires on 11/11/2035 and vests quarterly beginning October 1, 2025, becoming fully vested after three years. It is not exercisable until stockholder approval of an amendment to the incentive plan to increase available shares. The option vests in full upon a Change in Control.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a routine insider equity grant. A director received a stock option covering 10,000 shares on 11/11/2025 with an exercise price of $2.67 and an expiration date of 11/11/2035.
The option vests in quarterly installments beginning October 1, 2025, becoming fully vested after three years. It is not exercisable until stockholder approval is obtained for an amendment to the company’s incentive plan to increase shares available under the plan. The award vests in full upon a Change in Control as defined in the plan.
Apimeds Pharmaceuticals US, Inc. (APUS) disclosed a director stock option grant. On 11/11/2025, the reporting person acquired a stock option for 10,000 shares at an exercise price of $2.67, with an expiration date of 11/11/2035. The option was received for $0 and is held as Direct (D) ownership.
The award vests in quarterly installments beginning October 1, 2025 and will be fully vested after three years, subject to continued service on each vesting date. It is not exercisable until stockholder approval is obtained for an amendment to the Company’s incentive plan to increase available shares. The option will vest in full upon a Change in Control as defined in the plan.